
|Videos|January 21, 2014
The Black Swan Research Initiative® and a Paradigm Shift in the Treatment of Multiple Myeloma
Author(s)Brian G.M. Durie, MD
Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.
Advertisement
Clinical Pearls
Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses the Black Swan Research Initiative® of the IMF and a paradigm shift in the treatment of multiple myeloma.
- Many investigators are interested in the Black Swan Research Initiative to study minimal residual disease (MRD) or to study treatments that could achieve MRD-Zeroâ„¢
- Durie believes the time is right to not just compare treatments for multiple myeloma but to see if the disease is curable
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































